Intracellular immunization of human fetal cord blood stem/progenitor cells with a ribozyme against human immunodeficiency virus type 1

Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):699-703. doi: 10.1073/pnas.92.3.699.

Abstract

Successful treatment of human immunodeficiency virus infection may ultimately require targeting of hematopoietic stem cells. Here we used retroviral vectors carrying the ribozyme gene to transduce CD34+ cells from human fetal cord blood. Transduction and ribozyme expression had no apparent adverse effect on cell differentiation and/or proliferation. The macrophage-like cells, differentiated from the stem/progenitor cells in vitro, expressed the ribozyme gene and resisted infection by a macrophage tropic human immunodeficiency virus type 1. These results suggest the feasibility of stem cell gene therapy for human immunodeficiency virus-infected patients.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antigens, CD / analysis*
  • Antigens, CD34
  • Base Sequence
  • Cell Differentiation
  • Cell Division
  • Cells, Cultured
  • Colony-Forming Units Assay
  • DNA Polymerase III / genetics
  • Fetal Blood / cytology
  • Genetic Vectors
  • HIV-1 / physiology*
  • Hematopoietic Stem Cells* / immunology
  • Humans
  • Immunomagnetic Separation
  • Macrophages / virology*
  • Molecular Sequence Data
  • Promoter Regions, Genetic / genetics
  • RNA, Catalytic / biosynthesis
  • RNA, Catalytic / genetics*
  • Retroviridae
  • Transformation, Genetic
  • Virus Replication

Substances

  • Antigens, CD
  • Antigens, CD34
  • RNA, Catalytic
  • DNA Polymerase III